Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: Merck 3475 Pembrolizumab|RADIATION: Intraoperative radiation therapy (IORT)
Sponsor: Eileen Connolly
Collaborators: Merck Sharp & Dohme LLC